Loading
A phase 2 trial of Furmonertinib in non-small-cell lung cancer and small-cell lung cancer, run by RemeGen Co., Ltd., now recruiting.
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC is a phase 2 interventional study registered as NCT06962865 by RemeGen Co., Ltd., with 80 participants planned, started 2025-06-30 and due to reach its primary completion in 2026-05-31. Interventions recorded: RC108, Furmonertinib Mesilate Tablets Monotherapy. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.